CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-05-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Exercise or conversion | +1,875 | $0.00 | $0 | 7,033 |
| 2016-05-16 | Thomsen Jillian B. SVP & Chief Accounting Officer | Returned to the company · Restricted Stock Unit | −1,875 | 18,750 | ||
| 2016-04-25 | Lingnau Lutz Director | Exercise or conversion | +15,000 | $8.37 | $126K | 31,450 |
| 2016-04-25 | Lingnau Lutz Director | Sale | −15,000 | $16.27 | $244K | 16,450 |
| 2016-04-25 | Lingnau Lutz Director | Exercise or conversion · Stock Option | −15,000 | 0 | ||
| 2016-03-09 | Thomsen Jillian B. SVP & Chief Accounting Officer | Exercise or conversion | +15,000 | $6.65 | $100K | 20,158 |
| 2016-03-09 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −15,000 | $11.79 | $177K | 5,158 |
| 2016-03-09 | Thomsen Jillian B. SVP & Chief Accounting Officer | Exercise or conversion · Stock Option | −15,000 | 0 | ||
| 2016-02-17 | Gergel Ivan P. SVP & Chief Medical Officer | Sale | −556 | $11.92 | $7K | 694 |
| 2016-02-17 | Nicholson John SVP & Chief Financial Officer | Sale | −963 | $11.92 | $11K | 76,319 |
| 2016-02-17 | ROBIN HOWARD W President & CEO | Sale | −2,147 | $11.92 | $26K | 13,478 |
| 2016-02-17 | Doberstein Stephen K SVP & Chief Scientific Officer | Sale | −390 | $11.92 | $5K | 485 |
| 2016-02-17 | Thomsen Jillian B. SVP & Chief Accounting Officer | Sale | −716 | $11.92 | $9K | 5,158 |
| 2016-02-17 | Labrucherie Gil M SVP & General Counsel | Sale | −827 | $11.92 | $10K | 6,590 |
| 2016-02-17 | Hora Maninder SVP Pharma Dev & Mfg Ops | Sale | −963 | $11.92 | $11K | 5,803 |
| 2016-02-16 | Gergel Ivan P. SVP & Chief Medical Officer | Exercise or conversion | +1,250 | $0.00 | $0 | 1,250 |
| 2016-02-16 | Gergel Ivan P. SVP & Chief Medical Officer | Returned to the company · Restricted Stock Unit | −1,250 | 13,750 | ||
| 2016-02-16 | Nicholson John SVP & Chief Financial Officer | Exercise or conversion | +2,166 | $0.00 | $0 | 77,282 |
| 2016-02-16 | Nicholson John SVP & Chief Financial Officer | Returned to the company · Restricted Stock Unit | −2,166 | 23,834 | ||
| 2016-02-16 | ROBIN HOWARD W President & CEO | Exercise or conversion | +5,625 | $0.00 | $1 | 15,625 |
Page 53 of 55 · 1,088 trades